Oncology Biosimilars Market
Oncology Biosimilars Market Analysis by Drug Class (G-CSF, Monoclonal Antibody, Hematopoietic Agents), by Disease Indication (Breast Cancer, Colorectal Cancer, Neutropenia, Leukemia) by Distribution Channel, by Region - Global Insights 2022-2032
Analysis of Oncology Biosimilars market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Oncology Biosimilars Market Outlook (2022 to 2032)
The market for oncology biosimilars is anticipated to surge up at an astronomical pace, registering a CAGR of 11% during the forecast period from, and 2022 to 2032. As of 2021, the market was valued at US$ 4 Billion, and is likely to rise at a Y-o-Y growth rate of 5% in 2022 to reach US$ 4.2 Billion. By the end of the forecast period, the industry is poised to reach US$ 12 Billion.
|
Report Attributes |
Details |
|
Anticipated Base Year Value (2021) |
US$ 4 Billion |
|
Expected Market Value (2022) |
US$ 4.2 Billion |
|
Projected Forecast Value (2032) |
US$ 12 Billion |
|
Global Growth Rate (2022-2032) |
11% CAGR |
|
Growth Rate of the U.S (2022-2032) |
10.7% CAGR |
|
Expected Market Value of China (2032) |
US$ 5.6 Billion |
|
Key Oncology Biosimilars Service Providers |
|
The increased instances of cancer such as lung cancer and breast cancer, a susceptible ageing population, and an increase in research and development efforts done by numerous pharmaceutical firms have all contributed to the expansion of the oncology biosimilars market. Furthermore, increased patient awareness, advancements in treatment alternatives, and the high cost of biologics pharmaceuticals are some of the factors influencing the need for oncology biosimilars. Nonetheless, product recalls and rigorous regulations are factors impeding the growth of this industry.
Cancer is a lifestyle illness that emerges as a result of aberrant cell proliferation and can result in the creation of a tumor. Currently, the majority of successful cancer treatments is based on biological medications, commonly known as biologics, and comprises both targeted therapies and cancer immunotherapies. These medications are manufactured utilizing live creatures such as bacteria, yeast, and animal or plant cells, and they necessitate complicated production techniques and a lengthy development period.
As a result, the price of these medications is significantly greater, adding to the overall cost of cancer therapy. The creation of biosimilars of branded cancer biologics has grown in popularity as a means of lowering treatment costs. These biosimilars are extremely identical to the reference biologics in terms of efficacy and safety, and their reduced cost can help greatly reduce cancer treatment costs.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Oncology Biosimilars Market Revenue Analysis 2015 to 2021 vs. Future Outlook 2022 to 2032
Cancer is regarded as the second greatest cause of death worldwide. According to the World Health Organization, 9.6 million people died in 2018. To accommodate such a vast number of patients, pharmaceutical companies have increased their manufacture of cancer therapy medications.
Because blockbuster biologic medications are highly expensive, the ground is set for biosimilar and generic pharmaceuticals to enter the market. Based on these trends, the oncology biosimilars market is expected to grow at a fantastic CAGR of 11% by the end of 2032.
Prominent Oncology Biosimilars Industry Growth Drivers
The demand to Differentiate between Active and Inactive Components in Drugs has aided IN the Growth of Market
The requirement to distinguish active and inactive components in medications has aided in the spread of oncology biosimilars. Even when the reference component or medications stay the same, research analysts can distinguish pharmaceuticals based on their inactive components.
The significance of oncology biosimilars, which might have diverse activities on different types of malignancies, has aided in balancing the market's growth patterns. The enormous value of biosimilar medicines for cancer has also aided researchers in underlining the significance of oncology biosimilars.
FDA Approval of Various Biosimilars Exercises to Widen Oncology Biosimilars Deployment
The Food and Drug Administration (FDA) in the United States has been at the forefront of the worldwide oncology biosimilars market's growth. The FDA's approval of various biosimilars has proved beneficial to research firms and organizations. Following 2015, the FDA has been actively approving oncology biosimilars, a trend that is projected to gain traction in the coming years. The FDA has authorized two significant biosimilars: filgrastim-sndz (Zarxio) and bevacizumab-awwb (Mvasi). It will be fascinating to monitor how the increased rate of approvals affects market maturity.
Furthermore, the growing elderly population and environmental degradation have raised the prevalence of cancer globally throughout the years. These causes, together with the rising expense of cancer care, have increased the load on healthcare systems across the world. As a result, governments in a number of countries are encouraging the use of biosimilars as a cost-cutting approach. For example, the United States Food and Drug Administration (USFDA) have created educational materials for clinicians and patients concerning biosimilars.
Aside from that, the availability of low-cost medicine has been linked to earlier and wider therapeutic usage, as well as increased patient access. Furthermore, oncology biosimilars may enhance industry competitiveness, perhaps driving down the pricing of biological therapies even further. Other growth-inducing drivers for the market include impending patent expirations of branded biologics and increased R&D activity by biosimilar producers.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Key Challenges Prevalent in the Global Oncology Biosimilars Market
Manufacturing Problems related to Cancer Products containing Biosimilars may Impede Growth Prospects
The challenges in manufacturing associated with oncology biosimilars products are projected to stifle the expansion of the oncology biosimilars market. Regulatory and clinical barriers may also have an influence on market growth due to product approval delays, since biosimilars must undergo extra clinical trials before regulatory clearance.
Country-wise Analysis
What is the Growth Outlook for Oncology Biosimilars in the U.S?
Growing Investment in R&D to Establish Pipeline Portfolios widening Growth Opportunities
United States offers similarly enticing chances for expansion. A crucial growth engine for the region is the region's growing investment in R&D to establish pipeline portfolios. Biocon, a renowned Indian pharmaceutical business, holds three oncology pipeline biosimilars.
Apotex Inc. has five biosimilars under development. The firms collaborated to bring these medications to market. The US oncology biosimilars market is expected to grow at a CAGR of 10.7%, accounting for more than a quarter of the market.
How do Growth Prospects appear in the Chinese Market?
Focus on Active Collaboration within Market Giants to Drive the Chinese Oncology Biosimilars Market
The Chinese oncology biosimilars market is expected to develop rapidly, rising at a CAGR of 7.7% and achieving market domination. The Chinese market is expected to account for more than one-third of the total market.
This impressive growth trajectory is attributed to active collaboration within market giants to expand profit pools. For instance, in 2016, Dr. Reddy’s Laboratories collaborated with TR-Pharm to commercialize the former’s three biosimilars in Turkey.
Country-wise Forecast CAGRs in the Oncology Biosimilars Market
|
U.S |
10.7% |
|
U.K |
10% |
|
China |
7.7% |
|
Japan |
7.5% |
|
South Korea |
7.3% |
Category-wise Insights
Which is the Most Preferred Disease Indication Type?
Blood Cancer Segment to be Top Growth Driver in the Coming Years
During the projection period, the blood cancers category is expected to grow the quickest, at a staggering 10% CAGR. This is mostly due to an increase in the number of innovative medications in leading manufacturers' pipelines. The blood cancers category is expected to account for more than one-fifth of the entire oncology biosimilars market.
The neutropenia sector, on the other hand, is projected to dominate the worldwide Oncological biosimilars market, accounting for more than half of the overall market share. The expiration of patented blockbuster biologics has increased the use of biosimilar drugs in the category. In 2018, the FDA authorized Pfizer's filgrastim-aafi for the treatment of neutropenia in patients undergoing blood cancer therapy. The neutropenia market is expected to grow at a 7% CAGR.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
Celltrion, Inc., Dr. Reddy's Laboratories Ltd., Biocon, Teva Pharmaceutical Industries Ltd., and Sandoz International GmBH are the key participants in the worldwide oncology biosimilars market. As a result, it is a highly concentrated market. These market participants collectively account for more than 70% of the market share. To broaden their market footprints, these firms rely largely on active alliances to improve their product distribution networks.
- In 2018, Biocon, for example, established an exclusive global agreement with Sandoz on next-generation biosimilars. Similarly, Dr. Reddy's cooperated with TR Pharm in 2016 to offer three biosimilars in Turkey. Pfizer, Inc., Celltrion, Inc., Sandoz International GmBH, STADA Arzneimittel AG, and Apotex, Inc. are some of the other significant industry participants in the global oncology biosimilars market.
- Atos has announced recently in April 2022 that it intends to forge a 5-year contractual agreement to deliver managed services for digital operations, applications and cybersecurity for Independent Health (IH). Atos’ operational solutions will leverage infrastructure and digital platforms to optimize operating costs and generate efficiencies across the business landscape.
Key Segments Covered in the Oncology Biosimilars Industry Report
-
Oncology Biosimilars by Drug
- G-CSF
- Monoclonal Antibody
- Hematopoietic Agents
-
Oncology Biosimilars by Disease Indication
- Breast Cancer
- Non-Small Cell Lung Cancer
- Colorectal Cancer
- Neutropenia
- Blood Cancer
- Leukemia
- Myeloid Leukemia
- Chronic Lymphocytic Leukemia (CLL)
- Non-Hodgkin Lymphoma
- Others
-
Oncology Biosimilars by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
-
Oncology Biosimilars by Region
- North America
- Europe
- Asia Pacific
- Rest of the World
Table of Content
1. Preface 1.1. Market Definition and Scope 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Assumptions & Acronyms Used 2.2. Research Methodology 3. Executive Summary: Global Oncology Biosimilar Market 3.1. Executive Summary 3.2. Market Opportunity Map 3.3. Market Overview 3.4. Key Industry Developments 3.5. Global Oncology Biosimilar Market Size (US$ Mn) Forecast, 2022-2032 3.6. Global Oncology Biosimilar Market Outlook 4. Market Dynamics 4.1. Drivers 4.2. Restraints 4.3. Opportunity 4.4. Key Trends 5. Porter’s Five Force Analysis 6. Oncology Biosimilars: Key Molecules 7. Biosimilars Market Snapshot 8. Cancer Statistics 9. Global Oncology Biosimilars Market Analysis and Forecasts, By Drug Class 9.1. Introduction & Definition 9.2. Key Findings 9.3. Global Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032 9.4. Market Attractiveness by Drug Class 9.5. Global Oncology Biosimilars Market Forecast, by Drug Class, 2022-2032 9.5.1. G-CSF 9.5.2. Monoclonal Antibody 9.5.3. Hematopoietic Agents 9.6. Global Oncology Biosimilars Market Analysis, by Drug Class, 2022-2032 9.7. Key Trends 10. Global Oncology Biosimilars Market Analysis and Forecasts, By Disease Indication 10.1. Introduction & Definition 10.2. Key Findings 10.3. Global Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032 10.4. Market Attractiveness by Disease Indication 10.5. Global Oncology Biosimilars Market Forecast, by Disease Indication, 2022-2032 10.5.1. Breast Cancer 10.5.2. Non-Small Cell lung Cancer 10.5.3. Blood Cancer 10.5.3.1. Leukemia 10.5.3.1.1. Myeloid Leukemia 10.5.3.1.2. Chronic Lymphocytic Leukemia 10.5.3.1.3. Others 10.5.3.2. Non-Hodgkin Lymphoma 10.5.4. Colorectal Cancer 10.5.5. Neutropenia 10.5.6. Others 10.6. Global Oncology Biosimilars Market Analysis, by Disease Indication, 2022-2032 10.7. Key Trends 11. Global Oncology Biosimilars Market Analysis and Forecasts, By Distribution Channel 11.1. Introduction & Definition 11.2. Key Findings 11.3. Global Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032 11.4. Market Attractiveness By Distribution Channel 11.5. Global Oncology Biosimilars Market Forecast, by Distribution Channel, 2022-2032 11.5.1. Hospital Pharmacy 11.5.2. Online Pharmacy 11.5.3. Retail Pharmacy 11.6. Global Oncology Biosimilars Market Analysis, by Distribution Channel, 2022-2032 11.7. Key Trends 12. Global Oncology Biosimilars Market Analysis and Forecasts, By Region 12.1. Global Market Scenario 12.2. Global Oncology Biosimilars Market Value Share, by Region, 2022 and 2032 12.3. Global Oncology Biosimilars Market Attractiveness, by Region, 2022-2032 12.4. Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Region, 2022-2032 12.4.1. North America 12.4.2. Europe 12.4.3. Asia Pacific 12.4.4. Rest of the World 13. North America Oncology Biosimilars Market Analysis and Forecast 13.1. North America Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032 13.2. North America Oncology Biosimilars Market Value Share, by Country, 2022 and 2032 13.3. North America Oncology Biosimilars Market Attractiveness, by Country, 2022-2032 13.4. North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032 13.4.1. U.S. 13.4.2. Canada 13.5. North America Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032 13.6. North America Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032 13.7. North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032 13.7.1. G-CSF 13.7.2. Monoclonal Antibody 13.7.3. Hematopoietic Agents 13.8. North America Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032 13.9. North America Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032 13.10. North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032 13.10.1. Breast Cancer 13.10.2. Non-Small Cell lung Cancer 13.10.3. Blood Cancer 13.10.3.1. Leukemia 13.10.3.1.1. Myeloid Leukemia 13.10.3.1.2. Chronic Lymphocytic Leukemia 13.10.3.1.3. Others 13.10.3.2. Non-Hodgkin Lymphoma 13.10.4. Colorectal Cancer 13.10.5. Neutropenia 13.10.6. Others 13.11. North America Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032 13.12. North America Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032 13.13. North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032 13.13.1. Hospital Pharmacy 13.13.2. Online Pharmacy 13.13.3. Retail Pharmacy 13.14. Key Trends 14. Europe Oncology Biosimilars Market Analysis and Forecast 14.1. Europe Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032 14.2. Europe Oncology Biosimilars Market Value Share, by Country, 2022 and 2032 14.3. Europe Oncology Biosimilars Market Attractiveness, by Country, 2022-2032 14.4. Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032 14.4.1. U.K. 14.4.2. Germany 14.4.3. France 14.4.4. Italy 14.4.5. Russia 14.4.6. Spain 14.4.7. Rest of Europe 14.5. Europe Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032 14.6. Europe Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032 14.7. Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032 14.7.1. G-CSF 14.7.2. Monoclonal Antibody 14.7.3. Hematopoietic Agents 14.8. Europe Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032 14.9. Europe Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032 14.10. Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032 14.10.1. Breast Cancer 14.10.2. Non-Small Cell lung Cancer 14.10.3. Blood Cancer 14.10.3.1. Leukemia 14.10.3.1.1. Myeloid Leukemia 14.10.3.1.2. Chronic Lymphocytic Leukemia 14.10.3.1.3. Others 14.10.3.2. Non-Hodgkin Lymphoma 14.10.4. Colorectal Cancer 14.10.5. Neutropenia 14.10.6. Others 14.11. Europe Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032 14.12. Europe Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032 14.13. Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032 14.13.1. Hospital Pharmacy 14.13.2. Online Pharmacy 14.13.3. Retail Pharmacy 14.14. Key Trends 15. Asia Pacific Oncology Biosimilars Market Analysis and Forecast 15.1. Asia Pacific Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032 15.2. Asia Pacific Oncology Biosimilars Market Value Share, by Country, 2022 and 2032 15.3. Asia Pacific Oncology Biosimilars Market Attractiveness, by Country, 2022-2032 15.4. Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032 15.4.1. China 15.4.2. India 15.4.3. Japan 15.4.4. Australia & New Zealand 15.4.5. Rest of Asia Pacific 15.5. Asia Pacific Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032 15.6. Asia Pacific Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032 15.7. Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032 15.7.1. G-CSF 15.7.2. Monoclonal Antibody 15.7.3. Hematopoietic Agents 15.8. Asia Pacific Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032 15.9. Asia Pacific Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032 15.10. Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032 15.10.1. Breast Cancer 15.10.2. Non-Small Cell lung Cancer 15.10.3. Blood Cancer 15.10.3.1. Leukemia 15.10.3.1.1. Myeloid Leukemia 15.10.3.1.2. Chronic Lymphocytic Leukemia 15.10.3.1.3. Others 15.10.3.2. Non-Hodgkin Lymphoma 15.10.4. Colorectal Cancer 15.10.5. Neutropenia 15.10.6. Others 15.11. Asia Pacific Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032 15.12. Asia Pacific Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032 15.13. Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032 15.13.1. Hospital Pharmacy 15.13.2. Online Pharmacy 15.13.3. Retail Pharmacy 15.14. Key Trends 16. Rest of the World Oncology Biosimilars Market Analysis and Forecast 16.1. Rest of the World Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032 16.2. Rest of the World Oncology Biosimilars Market Value Share, by Country, 2022 and 2032 16.3. Rest of the World Oncology Biosimilars Market Attractiveness, by Country, 2022-2032 16.4. Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032 16.4.1. Mexico 16.4.2. Brazil 16.4.3. Rest of the World 16.5. Rest of the World Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032 16.6. Rest of the World Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032 16.7. Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032 16.7.1. G-CSF 16.7.2. Monoclonal Antibody 16.7.3. Hematopoietic Agents 16.8. Rest of the World Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032 16.9. Rest of the World Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032 16.10. Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032 16.10.1. Breast Cancer 16.10.2. Non-Small Cell lung Cancer 16.10.3. Blood Cancer 16.10.3.1. Leukemia 16.10.3.1.1. Myeloid Leukemia 16.10.3.1.2. Chronic Lymphocytic Leukemia 16.10.3.1.3. Others 16.10.3.2. Non-Hodgkin Lymphoma 16.10.4. Colorectal Cancer 16.10.5. Neutropenia 16.10.6. Others 16.11. Rest of the World Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032 16.12. Rest of the World Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032 16.13. Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032 16.13.1. Hospital Pharmacy 16.13.2. Online Pharmacy 16.13.3. Retail Pharmacy 16.14. Key Trends 17. Competition Landscape 17.1. Market Player – Competition Matrix (By Tier and Size of companies) 17.2. Market Share Analysis By Company (2021) 18. Company Profiles 18.1. Sandoz International GmbH 18.1.1. Company Details 18.1.2. Business Overview 18.1.3. Financial Overview 18.1.4. Strategic Overview 18.1.5. SWOT Analysis 18.2. Pfizer, Inc. 18.2.1. Company Details 18.2.2. Business Overview 18.2.3. Financial Overview 18.2.4. Strategic Overview 18.2.5. SWOT Analysis 18.3. Celltrion Inc. 18.3.1. Company Details 18.3.2. Business Overview 18.3.3. Financial Overview 18.3.4. Strategic Overview 18.3.5. SWOT Analysis 18.4. Dr. Reddy’s Laboratories Ltd. 18.4.1. Company Details 18.4.2. Business Overview 18.4.3. Financial Overview 18.4.4. Strategic Overview 18.4.5. SWOT Analysis 18.5. Biocon 18.5.1. Company Details 18.5.2. Business Overview 18.5.3. Financial Overview 18.5.4. Strategic Overview 18.5.5. SWOT Analysis 18.6. Teva Pharmaceutical Industries Ltd. 18.6.1. Company Details 18.6.2. Business Overview 18.6.3. Financial Overview 18.6.4. Strategic Overview 18.6.5. SWOT Analysis 18.7. STADA Arzneimittel AG 18.7.1. Company Details 18.7.2. Business Overview 18.7.3. Financial Overview 18.7.4. Strategic Overview 18.7.5. SWOT Analysis 18.8. Apotex Inc. (Apobiologix) 18.8.1. Company Details 18.8.2. Business Overview 18.8.3. Financial Overview 18.8.4. Strategic Overview 18.8.5. SWOT Analysis 18.9. Intas Pharmaceuticals Ltd. 18.9.1. Company Details 18.9.2. Business Overview 18.9.3. Financial Overview 18.9.4. Strategic Overview 18.9.5. SWOT Analysis 18.10. BIOCAD 18.10.1. Company Details 18.10.2. Business Overview 18.10.3. Financial Overview 18.10.4. Strategic Overview 18.10.5. SWOT Analysis
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Biosimilars Market Snapshot
Table 02: Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032
Table 03: Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032
Table 04: Global Oncology Biosimilars Market Size (US$ Mn) Forecast, Blood Cancer, 2022-2032
Table 05: Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2022-2032
Table 06: Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032
Table 07: Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Region, 2022-2032
Table 08: Approved Oncology Biosimilars by USFDA in new biosimilars pathway established under BPCIA Act
Table 09: North America Oncology Biosimilars: Pipeline Overview, 2017-2020
Table 10: North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032
Table 11: North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032
Table 12: Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032
Table 13: Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032
Table 14: Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032
Table 15: Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Blood Cancer, 2022-2032
Table 16: Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2022-2032
Table 17: Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032
Table 18: Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032
Table 19: Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032
Table 20: Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032
Table 21: Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Blood Cancer, 2022-2032
Table 22: Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2022-2032
Table 23: Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032
Table 24: Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032
Table 25: Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, Drug Class, 2022-2032
Table 26: Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032
Table 27: Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Blood Cancer, 2022-2032
Table 28: Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2022-2032
Table 29: Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Fig. 01: Global Oncology Biosimilars Market Size (US$ Mn) Forecast, 2022-2032
Fig. 02: Global Oncology Biosimilars Market Value Share, by Drug Class (2021)
Fig. 03: Global Oncology Biosimilars Market Value Share, by Disease Indication (2021)
Fig. 04: Global Oncology Biosimilars Market Value Share, by Distribution Channel (2021)
Fig. 05: Global Oncology Biosimilars Market Value Share, by Region (2021)
Fig. 06: U.S. Prevalence Share (%), By Cancer Type, 2015
Fig. 07: Global Estimation of Cancer, By New Cases & Deaths, 2021
Fig. 08: Global Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032
Fig. 09: Global Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032
Fig. 10: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Monoclonal Antibody, 2022-2032
Fig. 11: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hematopoietic Agents, 2022-2032
Fig. 12: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by G-CSF, 2022-2032
Fig. 13: Global Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032
Fig. 14: Global Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032
Fig. 15: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Breast Cancer, 2022-2032
Fig. 16: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Non-small Cell Lung Cancer, 2022-2032
Fig. 17: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Blood Cancer, 2022-2032
Fig. 18: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Colorectal Cancer, 2022-2032
Fig. 19: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Neutropenia, 2022-2032
Fig. 20: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2022-2032
Fig. 21: Global Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032
Fig. 22: Global Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032
Fig. 23: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacy, 2022-2032
Fig. 24: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Retail Pharmacy, 2022-2032
Fig. 25: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospital Pharmacy, 2022-2032
Fig. 26: Global Oncology Biosimilars Market Value Share, by Region, 2022 and 2032
Fig. 27: Global Oncology Biosimilars Market Attractiveness, by Region, 2022-2032
Fig. 28: North America Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032
Fig. 29: North America Oncology Biosimilars Market Value Share, by Country, 2022 and 2032
Fig. 30: North America Oncology Biosimilars Market Attractiveness, by Country, 2022-2032
Fig. 31: North America Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032
Fig. 32: North America Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032
Fig. 33: Europe Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032
Fig. 34: Europe Oncology Biosimilars Market Value Share, by Country, 2022 and 2032
Fig. 35: Europe Oncology Biosimilars Market Attractiveness, by Country, 2022-2032
Fig. 36: Europe Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032
Fig. 37: Europe Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032
Fig. 38: Europe Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032
Fig. 39: Europe Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032
Fig. 40: Europe Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032
Fig. 41: Europe Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032
Fig. 42: Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2022-2032
Fig. 43: Asia Pacific Oncology Biosimilars Market Value Share, by Country, 2022 and 2032
Fig. 44: Asia Pacific Oncology Biosimilars, Market Attractiveness, by Country, 2022-2032
Fig. 45: Asia Pacific Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032
Fig. 46: Asia Pacific Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032
Fig. 47: Asia Pacific Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032
Fig. 48: Asia Pacific Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032
Fig. 49: Asia Pacific Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032
Fig. 50: Asia Pacific Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032
Fig. 51: Rest of the World Oncology Biosimilars, Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2022-2032
Fig. 52: Rest of the World Oncology Biosimilars Market Value Share, by Country, 2022 and 2032
Fig. 53: Rest of the World Oncology Biosimilars, Market Attractiveness, by Country, 2022-2032
Fig. 54: Rest of the World Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032
Fig. 55: Rest of the World Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032
Fig. 56: Rest of the World Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032
Fig. 57: Rest of the World Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032
Fig. 58: Rest of the World Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032
Fig. 59: Rest of the World Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032
Fig. 60: Global Oncology Biosimilars Market Share, by Company, 2021
Fig. 61: Breakdown of Net Sales of Sandoz International GmbH (A Novartis Division), by Franchise, 2021 (%)
Fig. 62: Revenue (US$ Bn) & Y-o-Y Growth (%) of Sandoz International GmbH (A Novartis Division), 2015-2021
Fig. 63: Breakdown of Net Sales of Pfizer, Inc., by Region, 2021 (%)
Fig. 64: Revenue (US$ Bn) & Y-o-Y Growth (%) of Pfizer, Inc., 2015-2021
Fig. 65: Breakdown of Net Sales of Celltrion Inc., by Business Segments, 2021
Fig. 66: Revenue (US$ Mn) & Y-o-Y Growth (%) of Celltrion Inc., 2015-2021
Fig. 67: Breakdown of Net Sales of Dr. Reddy’s Laboratories Ltd., by Business Segments, 2021 (%)
Fig. 68: Revenue (US$ Bn) & Y-o-Y Growth (%) of Dr. Reddy’s Laboratories Ltd., 2015-2021
Fig. 69: Breakdown of Net Sales of Biocon, by Business Segments, 2021 (%)
Fig. 70: Revenue (US$ Mn) & Y-o-Y Growth (%) of Biocon, 2015-2021
Fig. 71: Breakdown of Net Sales of Teva Pharmaceutical Industries Ltd., by Business Segments, 2021 (%)
Fig. 72: Revenue (US$ Bn) & Y-o-Y Growth (%) of Teva Pharmaceutical Industries Ltd., 2015-2021
Fig. 73: Breakdown of Net Sales of STADA Arzneimittel AG, by Business Segments, 2021 (%)
Fig. 74: Revenue (US$ Bn) & Y-o-Y Growth (%) of STADA Arzneimittel AG, 2015-2021
Fig. 75: Revenue (US$ Mn) & Y-o-Y Growth (%) of Intas Pharmaceuticals Ltd., 2015-2021
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What was the market worth for oncology biosimilars in 2021?
As of 2021, Fact.MR estimated the Oncology Biosimilars market to have reached US$ 3.5 Billion
What is the expected worth of the oncology biosimilars industry in 2022?
By 2022, Fact.MR expected demand for oncology biosimilars to reach US$ 4.2 Billion
At what CAGR did the oncology biosimilars market flourish from 2015-2021?
From 2015-2021, the oncology biosimilars market grew at a 9% value CAGR
What is the expected forecast CAGR for Oncology Biosimilars from 2022-2032?
From 2022-2032, Oncology Biosimilars demand is likely to surge at an 11% CAGR
At what value will the market for oncology biosimilars close in 2032?
By 2032, the market for Oncology Biosimilars is likely to be valued at US$ 12 Billion
What is the expected market value for the U.S oncology biosimilars market?
By 2032, Fact.MR expects the U.S market for Oncology Biosimilars to reach US$ 5.6 Billion
How opportunistic is the Chinese market for oncology biosimilars?
China is expected to register a 7.7% CAGR with regard to the oncology biosimilars industry
What is the expected growth rate for the Japanese market?
Japan is expected to document a CAGR worth 7.5% in the Oncology Biosimilars market
Which disease Indication type will account for the maximum oncology biosimilars revenue?
Blood cancer segment will expand the fastest, expanding at a 10% CAGR
Oncology Biosimilars Market